688266 logo

Suzhou Zelgen Biopharmaceuticals Co., Ltd. Stock Price

SHSE:688266 Community·CN¥27.4b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 1 Fair Values set on narratives written by author

688266 Share Price Performance

CN¥103.68
38.57 (59.24%)
CN¥103.68
38.57 (59.24%)
Price CN¥103.68

688266 Community Narratives

There are no narratives available yet.

Snowflake Analysis

Exceptional growth potential with adequate balance sheet.

1 Risk
3 Rewards

Suzhou Zelgen Biopharmaceuticals Co., Ltd. Key Details

CN¥742.3m

Revenue

CN¥67.6m

Cost of Revenue

CN¥674.6m

Gross Profit

CN¥808.0m

Other Expenses

-CN¥133.3m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Nov 05, 2025
-0.50
90.89%
-17.96%
97.1%
View Full Analysis

About 688266

Founded
2009
Employees
910
CEO
Zelin Sheng
WebsiteView website
www.zelgen.com

Suzhou Zelgen Biopharmaceuticals Co., Ltd. researches and develops, manufactures, and sells medicines in the People's Republic of China. It offers donafenib tablets; recombinant human thrombin for topincal use; jacktinib tablets; and recombinant human thyroid-stimulating hormone for injection; obeticholic acid magnesium tablets; ZG19018 tablets; ZG005 powder for injection; and alkotinib capsules for the treatment of liver cancer, non-small cell lung cancer, small cell lung cancer, colorectal cancer, thyroid cancer, and neuroendocrine cancer, as well as multiple therapeutic areas, such as bleeding, hepatobiliary diseases, and autoimmune diseases. The company was founded in 2009 and is based in Kunshan, the People's Republic of China.

Recent 688266 News & Updates

Recent updates

No updates